Hypertension Care: It’s Time to Act - European Medical Journal

Hypertension Care: It’s Time to Act

Download PDF
Josep Redòn,1 Anthony Heagerty2
Michel Burnier,3 Luis M. Ruilope,4 Roland Schmieder,5 Thomas Weiss,6 Massimo Volpe7

Josep Redòn is a consultant to Daiichi Sankyo and the Menarini group. Anthony Heagerty is  a consultant to Daiichi Sankyo and has spoken for Daiichi Sankyo and Menarini. Michel Burnier is a  consultant to Daiichi Sankyo and the Menarini group. Luis Ruilope has served as an advisor and speaker to Daiichi Sankyo. Roland Schmieder has received grants for his institution from Daiichi Sankyo and is a member of a speakers’ bureau, and advisor to Daiichi Sankyo and the Menarini group. Thomas Weiss has received grants and is an advisor for Daiichi Sankyo, and has received lecture fees from Menarini and Daiichi Sankyo. Massimo Volpe received the Award University of Rome Sapienza from the Italian  Ministry of Health; he is a member of a speakers’ bureau for Menarini International and Daiichi Sankyo Europe, and a consultant/member of an advisory board for Takeda International, Daiichi Sankyo Europe, Actelion, and Novartis Pharmaceuticals Ltd.


Writing assistance was provided by Dr Lynda McEvoy, apothecom scopemedical Ltd.


Please refer to the approved SmPC for the correct use of the drugs mentioned in this article.


The publication of this article was funded by Menarini. The views and opinions expressed are  those of the authors and not necessarily of Menarini.

EMJ Cardiol. ;31:2-10. DOI/10.33590/emjcardiol/10310492. https://doi.org/10.33590/emjcardiol/10310492.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The satellite symposium was held in two separate sessions – the first a traditional symposium format, and  the second as an interactive panel discussion in which the faculty answered questions from the delegates.  The symposium objectives included consideration of the impact of suboptimal blood pressure (BP) control  on the high levels of cardiovascular (CV) events in Europe; evaluation of the importance of patient  adherence in improving management of BP; consideration of the management of treatment-resistant  patients; discussion of a new initiative to drive improved management of hypertension; and how angiotensin receptor blocker (ARB)-based treatments and single-pill combinations may be used to treat hypertensive patients. Professor Burnier discussed the difficulties associated with achieving good BP control in the primary care setting and highlighted the utility of single-pill fixed-dose combinations (FDCs) for improving adherence and BP normalisation. Professor Ruilope discussed the clinical work-up and management of patients with treatment-resistant hypertension, while Professors Schmieder and Weiss outlined some initiatives taking place that aim to improve BP control rates. Finally, Professor Volpe described an  ARB-based treatment platform which shows how patients can be effectively treated with single-pill combination therapy.

Please view the full content in the PDF above. 

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally